Mesenchymal Stroma Cells (MSC) in Autoimmune Diseases: Clinical Application in Systemic Sclerosis and in Systemic Lupus Erythematosus (ICBMT 2025) - Sep 3, 2025 - Abstract #JS05-3; Pres time: Sep 13, 2025; 09:00 AM - 10:30 AM; "Despite the recent regulatory approval of several drugs (belimumab, anifrolumab, and voclosporin) as add-on to standard of care, more effective and safe treatments are needed for a large number of patients with SLE. 2024 Dec 17:S2665-9913(24)00298 5) Lindsay D et al Mesenchymal stromal cells, autoimmune disease, immunomodulation, standardization, clinical trial design, data reporting. Cytotherapy 2025"
Clinical • Stroma • Acute Graft versus Host Disease • Fibrosis • Graft versus Host Disease • Immunology • Inflammatory Arthritis • Lupus • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis
|